Last reviewed · How we verify
KPG-818 mid dose
At a glance
| Generic name | KPG-818 mid dose |
|---|---|
| Sponsor | Kangpu Biopharmaceuticals, Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase 1b/2a Study to Evaluate Safety and Efficacy of KPG-818 in SLE (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |